SURVIVAL TIME OF PATIENTS WITH MELIOIDOSIS; AN APPLICATION OF KAPLAN–MEIER SURVIVAL ANALYSIS
DOI:
https://doi.org/10.37268/mjphm/vol.24/no.2/art.2248Keywords:
Burkholderia pseudomallei; melioiodosis; median survival time; Kaplan-meier; risk factorsAbstract
Melioidosis is a contagious infection caused by the gram-negative bacteria – Burkholderia pseudomallei. The modes of acquisition are inhalation, ingestion, and inoculation. Misdiagnosis of melioidosis is frequently reported due to limited awareness of the disease and confusion with tuberculosis. Antibiotic resistance of causative agent, age group, and organ involved are the prognostic factors contributing to melioidosis's high fatality. Hence, the purpose of this current research was to compare the survival probability in melioidosis patients according to the prognostic factors. This study documented 453 cases from Kedah and Perlis from 2014 until 2018 using a retrospective method. Patient’s medical information related to the study was extracted using a data collection sheet. All the data were analyzed using IBM SPSS Statistics. Kaplan-Meier Survival Analysis was used to determine the 5-year survival and median survival time. In contrast, the Log-rank test was used to compare the survival probability based on the demographics, underlying diseases, and prognostic factors. The overall 5-year survival was 85%, and the median survival time of melioidosis patients was 30 days. Prognostic factors that cause a significant difference in survival probability and median survival time of melioidosis patients were age group above 40 years old, diabetes mellitus and chronic lung disease as comorbidities, and bacteremia melioidosis. Melioidosis should be classified as an opportunistic infection that has high mortality in the immunocompromised host. Early diagnosis and appropriate treatment can increase the survival advantages of melioidosis patients.
References
S. D. Puthucheary, “Melioidosis in Malaysia,” Med. J. Malaysia, vol. 64, no. 4, pp. 266–274, 2009, doi: 10.4269/ajtmh.1969.18.703.
N. S. K. Ramli, C. Eng Guan, S. Nathan, and J. Vadivelu, “The Effect of Environmental Conditions on Biofilm Formation of Burkholderia pseudomallei Clinical Isolates,” PLoS One, vol. 7, no. 9, 2012, doi: 10.1371/journal.pone.0044104.
S. Nathan et al., “Melioidosis in Malaysia: Incidence, clinical challenges, and advances in understanding pathogenesis,” Trop. Med. Infect. Dis., vol. 3, no. 1, 2018, doi: 10.3390/tropicalmed3010025.
White NJ, “Melioidosis,” Lancet, no. 17, p. 361, 2003.
K. Mardhiah, N. Wan-Arfah, N. N. Naing, M. R. A. Hassan, and H. K. Chan, “Predictors of in-hospital mortality by logistic regression analysis among melioidosis patients in Northern Malaysia: A retrospective study,” Asian Pac. J. Trop. Med., vol. 14, no. 8, pp. 356–363, 2021, doi: 10.4103/1995-7645.321612.
K. Mardhiah, N. Wan-arfah, N. N. Naing, M. Radzi, A. Hassan, and H. Chan, “The Cox model of predicting mortality among melioidosis patients in Northern Malaysia,” vol. 25, no. November 2020, 2021.
K. Mardhiah, N. Wan-Arfah, N. Naing, M. Hassan, and H. K. Chan, “Comparison of Cox proportional hazards model, Cox proportional hazards with time-varying coefficients model, and lognormal accelerated failure time model: Application in time to event analysis of melioidosis patients,” Asian Pac. J. Trop. Med., vol. 15, no. 3, pp. 128–134, 2022, doi: 10.4103/1995-7645.340568.
A. R. Zueter, C. Y. Yean, M. Abumarzouq, Z. A. Rahman, Z. Z. Deris, and A. Harun, “The epidemiology and clinical spectrum of melioidosis in a teaching hospital in a North-Eastern state of Malaysia: A fifteen-year review,” BMC Infect. Dis., vol. 16, no. 1, pp. 1–11, 2016, doi: 10.1186/s12879-016-1583-2.
D. Limmathurotsakul et al., “Risk Factors for Recurrent Melioidosis in Northeast Thailand,” Clin. Infect. Dis., vol. 43, no. 8, pp. 979–986, 2006, doi: 10.1086/507632.
G. C. K. W. Koh et al., “Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis,” Clin. Infect. Dis., vol. 52, no. 6, pp. 717–725, 2011, doi: 10.1093/cid/ciq192.
B. Kronsteiner et al., “Diabetes alters immune response patterns to acute melioidosis in humans,” Eur. J. Immunol., vol. 49, no. 7, pp. 1092–1106, 2019, doi: 10.1002/eji.201848037.
C. M. Weyand and J. J. Goronzy, “Aging of the immune system: Mechanisms and therapeutic targets,” Ann. Am. Thorac. Soc., vol. 13, no. December, pp. S422–S428, 2016, doi: 10.1513/AnnalsATS.201602-095AW.
Hantrakun, V. et al. "Clinical epidemiology of 7126 melioidosis patients in Thailand and the implications for a national notifiable diseases surveillance system," Open Forum Infectious Diseases, 6(12), 2015. doi: 10.1093/ofid/ofz498.
Hanson, J. and Smith, S. "High rates of premature and potentially preventable death among patients surviving melioidosis in Tropical Australia," American Journal of Tropical Medicine and Hygiene, 101(2), pp. 328–331, 2019. doi: 10.4269/ajtmh.19-0375.
Currie, B. J., Ward, L. and Cheng, A. C. "The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year darwin prospective study," PLoS Neglected Tropical Diseases, 4(11), 2010. doi: 10.1371/journal.pntd.0000900.
A. C. Cheng et al., “Clinical definitions of melioidosis,” Am. J. Trop. Med. Hyg., vol. 88, no. 3, pp. 411–413, 2013, doi: 10.4269/ajtmh.12-0555.
Yaacob, Najib Majdi. (2015). Simple Random Sampling Using Excel by NajibMY. 10.13140/RG.2.1.2985.6728.
Churuangsuk, C. et al. "Characteristics, clinical outcomes and factors influencing mortality of patients with melioidosis in southern Thailand: A 10-year retrospective study," Asian Pacific Journal of Tropical Medicine, 9(3), pp. 256–260, 2016. doi: 10.1016/j.apjtm.2016.01.034.
Chien, J. M. F. et al. "Factors affecting clinical outcomes in the management of melioidosis in Singapore: a 16-year case series", BMC infectious diseases, 18(1), p. 482, 2018. doi: 10.1186/s12879-018-3393-1.
J. L. Jin and Y. X. Ning, “Septicemic melioidosis: A case report and literature review,” J. Thorac. Dis., vol. 6, no. 2, pp. 1–4, 2014, doi: 10.3978/j.issn.2072-1439.2014.01.20.
Roslani, A. D. R. M. et al. "Short report: Predictors of severe disease in Melioidosis patients in Kuala Lumpur, Malaysia," American Journal of Tropical Medicine and Hygiene, 91(6), pp. 1176–1178, 2014. doi: 10.4269/ajtmh.14-0354.
A. M. Zueter, M. Abumarzouq, M. I. Yusof, W. F. Wan Ismail, and A. Harun, “Osteoarticular and soft-tissue melioidosis in Malaysia: Clinical characteristics and molecular typing of the causative agent,” J. Infect. Dev. Ctries., vol. 11, no. 1, pp. 28–33, 2017, doi: 10.3855/jidc.7612.
P. V. Kingsley, M. Leader, N. S. Nagodawithana, M. Tipre, and N. Sathiakumar, “Melioidosis in Malaysia: A Review of Case Reports,” PLoS Negl. Trop. Dis., vol. 10, no. 12, pp. 1–18, 2016, doi: 10.1371/journal.pntd.0005182.
J. Waiwarawooth, K. Jutiworakul, and W. Joraka, “Epidemiology and clinical outcome of melioidosis at Chonburi Hospital, Thailand,” J. Infect. Dis. Antimicrob. Agents, vol. 25, no. 1, pp. 1–11, 2008.
Mardhiah, K. “A Review of the Study Designs and Statistical Methods Used in the Determination of Predictors of Melioidosis Mortality in Malaysia: 2010–2021,” Preprints 2023, 2023121592. https://doi.org/10.20944/preprints202312.1592.v1
M. R. Abu Hassan et al., “Socio-epidemiological and land cover risk factors for melioidosis in Kedah, Northern Malaysia,” PLoS Negl. Trop. Dis., vol. 13, no. 3, 2018, doi: 10.1371/journal.pntd.0007243.
Toh, V., Tee, S.P. and Lee, S.-H., “Clinical characteristics and predictors of mortality in patients with melioidosis: the Kapit experience,” Trop Med Int Health, 26: 664-671, 2021. https://doi.org/10.1111/tmi.13563
